Home > Insider Trading > Filing (0001104659-22-053625)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1429260	Fortress Biotech Inc.	FBIO	Pharmaceutical Preparations (2834)	205157386

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1647971	Dov Klein	C/O Fortress Biotech, Inc. 1111 Kane Concourse Suite 301 Bay Harbor Island FL 33154		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock, Par Value $0.001	Acquisiton	2021-08-05	305	$0.00	655,305	No	4	J	Direct
Common Stock, Par Value $0.001	Acquisiton	2021-09-30	480	$0.00	655,785	No	4	J	Direct
Common Stock, Par Value $0.001	Acquisiton	2021-11-16	230	$0.00	656,015	No	4	J	Direct
Common Stock, Par Value $0.001	Disposition	2021-12-28	5,000	$2.45	651,015	No	4	S	Direct
Common Stock, Par Value $0.001	Acquisiton	2022-01-01	100,000	$0.00	751,015	No	4	A	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	J	Direct
No	4	J	Direct
No	4	J	Direct
No	4	S	Direct
No	4	A	Direct

Footnotes

The shares were issued as a dividend pursuant to the Dividend Payment and Exchange Agreement executed by Fortress Biotech, Inc. on March 31, 2021 in favor of the holders of Journey Medical Corporation's 8% Cumulative Convertible Class A Preferred Stock.
The total holdings include 480,000 shares of deferred restricted stock and 40,000 shares underlying deferred restricted stock units.
The shares were issued upon the consummation of Journey Medical Corporation ("Journey's") initial public offering as a partial dividend pursuant to the Dividend Payment and Exchange Agreement executed by Fortress Biotech, Inc. on March 31, 2021 in favor of the holders of Journey's 8% Cumulative Convertible Class A Preferred Stock.
One-third of the shares will vest on each of January 1, 2023, 2024 and 2025, subject to continued service. The reporting person elected to defer 80,000 of these restricted shares pursuant to the issuer's Deferred Compensation Plan for Directors and instead received deferred share units that are subject to the same vesting conditions. Vested deferred shares will be delivered to the reporting person in January of the year following the reporting person's termination of service, or earlier upon his death or change in control of the issuer.
The total holdings include 560,000 shares of deferred restricted stock and 40,000 shares underlying deferred restricted stock units.